- Program
-
Sessions
- SESSION I
- Aldosterone Receptor antagonists clinical interest: Beyond the “Aldosterone escape” concept
- Relationship between Aldosterone and clinical parameters in dogs with Mitral Valve Disease
- Where are we with aldosterone escape (Break-through) in 2011?
- SESSION I
- SESSION II
- Targeting the Aldosterone pathway in cardiovascular disease
- Treatment of preserved cardiac function heart failure with an Aldosterone antagonist: the NHLBI TOPCAT Trial
- The DELAY STUDY (DElay of Appearance of sYmptoms of canine degenerative mitral valve disease treated with Spironolactone and Benazepril)
- SESSION II
- SESSION III
- How to use biomarkers in cardiology ?
- Potential markers of cardiac remodeling and function
- SESSION III
- SESSION IV
- A rock and a hard place: cardiorenal syndrome in clinical canine veterinary patients
- Cardio-Renal syndromes: Lessons from Human pathophysiology
- Mineralocorticoid receptor antogonists: New therapeutic opportunities in chronic kidney diseases
- SESSION IV
- Conclusion to CardioSymposium 2011
- Introduction to Symposium
- Speakers
- Footer links
CARDIO SYMPOSIUM 2011
